ABBOTT LABORATORIES — Director's Dealing 2020

Jan 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-01-27

Reporting Person: MANNING JOSEPH J (Senior Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-27	Common shares without par value	M	37500	$38.40	Acquired	88032	Direct
2020-01-27	Common shares without par value	S	37500	$89.5843	Disposed	50534	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-27	Option (right to buy)	$38.40	M	37500	Disposed	2026-02-18	Common shares (37500)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.52 to $89.65, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Includes shares acquired pursuant to a dividend reinvestment feature.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.